<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623086</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008108</org_study_id>
    <nct_id>NCT04623086</nct_id>
  </id_info>
  <brief_title>Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose</brief_title>
  <acronym>GLIDING</acronym>
  <official_title>A Randomized Comparison of Transitioning From Insulin GLargine to Insulin Degludec usING a Bridging Dose of Glargine Versus Direct Conversion, in Patients With Type 1 Diabetes Mellitus - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates direct switching vs use of a bridging dose from insulin glargine to&#xD;
      insulin degludec in type 1 DM patients. Half of the participants will receive a bridging&#xD;
      insulin glargine dose along with the 1st dose of degludec, while other half will receive a&#xD;
      placebo and 1st dose of degludec.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin degludec (IDeg), an ultra-long-acting basal insulin, is increasingly used to treat&#xD;
      patients with type 1 diabetes (T1D). IDeg has a half-life of 25 hours and duration of action&#xD;
      exceeding 42 hours in patients with T1D and as a result does not require as stringent a&#xD;
      dosing schedule as other basal insulins. However, steady state concentration of IDeg is not&#xD;
      reached until 2 to 3 doses are administered daily, and this may result in greater glycemic&#xD;
      variability in the 24 to 72 hours following the initiation of therapy with IDeg.&#xD;
&#xD;
      Our hypothesis is that among patients who transition from insulin glargine to IDeg, those who&#xD;
      use a bridging dose of insulin glargine will not have a significant change, on average, in&#xD;
      time spent in target glycemic range during the transition period, whereas, those&#xD;
      transitioning directly to IDeg will have a significant change in this parameter. We further&#xD;
      hypothesize that those using the bridging dose of insulin glargine will have less&#xD;
      hypoglycemia, less hyperglycemia and need fewer correction boluses than the direct-conversion&#xD;
      patients during the transition period.&#xD;
&#xD;
      Though IDeg is being increasingly used in clinical practice, there are no guidelines on what&#xD;
      is the best way to transition patients from other long-acting insulins, such as glargine, to&#xD;
      IDeg. The package insert recommends 1:1 dose conversion from other basal insulins to IDeg,&#xD;
      but this does not account for the time taken by IDeg to achieve steady state (typically 48-72&#xD;
      hours). There is no guidance on what to do in those 48-72 hours. Given the time taken for&#xD;
      IDeg to achieve steady state, the period of transition from one insulin to another, can&#xD;
      result in significant glycemic variation in the 24-72 hours after the first dose. We want to&#xD;
      study how best to avoid or minimize this and the option of using a small dose of their&#xD;
      original long-acting insulin has anecdotal evidence of success in our practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in percent time in range</measure>
    <time_frame>4 days</time_frame>
    <description>Change in percent time spent in target glycemic range (TIR, glucose 70-180 mg/dL, both values included) in the 48 hours before and the 48 hours after the 1st dose of IDeg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation (CV) of percent-time-in-range</measure>
    <time_frame>4 days</time_frame>
    <description>Change in CV in the 48 hours before and the 48 hours after the 1st dose of IDeg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal percent time in range of 70-180 mg/dL</measure>
    <time_frame>4 days</time_frame>
    <description>Change in the nocturnal percent time in range in the 48 hours before and the 48 hours after the 1st dose of IDeg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time above 180 mg/dL (TAR-1), percent time above 250 mg/dL (TAR-2)</measure>
    <time_frame>4 days</time_frame>
    <description>Change in the percent time above range (TAR-1, TAR-2) in the 48 hours before and the 48 hours after the 1st dose of IDeg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time below 70 mg/dL (TBR-1), percent time below 54 mg/dL (TBR-2)</measure>
    <time_frame>4 days</time_frame>
    <description>Change in the percent time below range (TBR-1, TBR-2) in the 48 hours before and the 48 hours after the 1st dose of IDeg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of correction boluses</measure>
    <time_frame>4 days</time_frame>
    <description>Change in the absolute number of correction boluses in the 48 hours before and the 48 hours after the 1st dose of IDeg.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine and Insulin Degludec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Degludec and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Degludec</intervention_name>
    <description>Insulin Degludec injection</description>
    <arm_group_label>Insulin Degludec and placebo</arm_group_label>
    <arm_group_label>Insulin Glargine and Insulin Degludec</arm_group_label>
    <other_name>Tresiba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Insulin Glargine injection</description>
    <arm_group_label>Insulin Glargine and Insulin Degludec</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection</description>
    <arm_group_label>Insulin Degludec and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet ALL inclusion criteria to be included in the study.&#xD;
&#xD;
               1. Patient age is 18-75 years.&#xD;
&#xD;
               2. Diagnosis of T1D of at least 1-year duration.&#xD;
&#xD;
               3. Has the ability to provide informed consent before any trial-related activities.&#xD;
&#xD;
               4. Treated with insulin glargine as their basal insulin in the 3 months preceding&#xD;
                  screening visit.&#xD;
&#xD;
               5. Stable insulin regimen (defined as change of &lt;20% in the total daily dose of&#xD;
                  insulin and no change to the basal insulin agent) over the 3 months preceding the&#xD;
                  screening visit.&#xD;
&#xD;
               6. Patient willing to dose their basal insulin at bedtime.&#xD;
&#xD;
               7. Hemoglobin A1c &lt; 9% in the 3 months preceding screening visit.&#xD;
&#xD;
               8. Able to self-administer their insulin doses.&#xD;
&#xD;
               9. Able to do self-monitoring of blood glucose using a glucose meter and willing to&#xD;
                  do this at least 2 times daily for patients using a CGM that requires calibration&#xD;
                  prior to the study and 4 times daily for patients who were not using a CGM prior&#xD;
                  to the study.&#xD;
&#xD;
              10. Agreeable to the use of a continuous glucose monitor (CGM) for the duration&#xD;
                  required in the study. If already using a CGM prior to the study, then agreeable&#xD;
                  to wearing the blinded study CGM concurrently during the study period.&#xD;
&#xD;
              11. Will be reachable by phone and/or email to comply with study procedures.&#xD;
&#xD;
              12. Will be able to comply with study procedures, per investigator's opinion.&#xD;
&#xD;
              13. Patient agrees to not use correctional insulin unless BG â‰¥250 for the 48 hours&#xD;
                  before and after 1st dose of IDeg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient must not have ANY of the exclusion criteria to be included in the study.&#xD;
&#xD;
               1. Patients with eGFR &lt;30 on at least 2 measurements within 1-year of the screening&#xD;
                  visit.&#xD;
&#xD;
               2. History of myocardial infarction within 6 months preceding the screening visit.&#xD;
&#xD;
               3. Patients taking non-insulin medications for the glycemic management of T1D&#xD;
                  (including metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2&#xD;
                  inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, pramlintide)&#xD;
&#xD;
               4. Known or suspected allergy to IDeg or one of its excipients.&#xD;
&#xD;
               5. Pregnant, planning to become pregnant in the next 3 months or breastfeeding.&#xD;
&#xD;
               6. Participation in a clinical trial with investigational drug within 1 month of the&#xD;
                  screening visit or at present.&#xD;
&#xD;
               7. Skin condition that prevents the insertion of the CGM.&#xD;
&#xD;
               8. Previously randomized and received drug in this study.&#xD;
&#xD;
               9. Presence of decompensated or poorly controlled psychiatric conditions.&#xD;
&#xD;
              10. Current known or suspected illicit substance use.&#xD;
&#xD;
              11. Any anticipated surgery or procedure in the next 14 days.&#xD;
&#xD;
              12. Patients using U-300 glargine as their basal insulin.&#xD;
&#xD;
              13. Patients using insulin afrezza as their short-acting insulin.&#xD;
&#xD;
              14. Use of glucocorticoid burst/pulse therapy within 14 days prior to screening visit&#xD;
                  (chronic stable glucocorticoid doses are acceptable).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthi Thirumalai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dori Khakpour</last_name>
    <phone>206-598-4882</phone>
    <email>dorik@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington Medicine Diabetes Institute at South Lake Union</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dori Khakpour</last_name>
      <phone>206-945-4965</phone>
      <email>dorik@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julia Chang</last_name>
      <phone>206.616.5091</phone>
      <email>juliac95@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Arthi Thirumalai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Chao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Arthi Thirumalai</investigator_full_name>
    <investigator_title>Assistant Professor, School of Medicine: Metabolism, Endocrinology and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Insulin glargine, insulin degludec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

